Thank you for joining us today.

As you just discovered, biotech's third turning point is finally here… but it’s arrived during the broadest, deepest, and longest bear market the industry has ever seen.

This situation is what Erez Kalir calls the greatest financial paradox of all time – a rare, once-in-a-generation opportunity for you to buy the world’s most exciting biotechs for pennies on the dollar.

A true asymmetric opportunity because for the first time ever – and perhaps the only time – biotech is a value play where you can get in at blood-in-the-streets prices…

…and go for potentially massive returns when this paradox comes to a screeching halt.

While we can’t say when this paradox will end, it will end eventually… and when it does we believe the returns could be truly remarkable.

Because during a biotech bull market, while the mainstream biotech indices and large-caps can increase by 100% or 200%… the small-caps Erez targets have the potential to increase by several times.

• Sangamo Therapeutics – 875% in less than 24 months…

• Ionis Pharmaceuticals – a biotech developing drugs for spinal muscular atrophy delivered investors returns of over 1,000%…

• Insmed went from below $3 to $20 after receiving FDA approval from its cystic fibrosis treatment…

• And these are actually relatively small returns for what’s possible in biotech, you also have firms like Keryx Biopharmaceuticals soaring over 17,000%…

• Or Pharmacyclics returning more than 45,000% after it was bought out by Big Pharma giant AbbVie.

However, this sector moves with blinding speed, so if you want to take advantage of the upside potential, it’s best to get in before the bull market begins.

That’s why it’s essential that we get Erez Kalir’s new report, Biotech’s Tipping Point, into your hands ASAP because inside you’ll not only get all the details of this transformational period…

…you’ll also get The Advanced Genetic Medicines Watchlist.

These are the 10 companies Erez just added to his watchlist.

10 small-caps that are leading the field in biotech’s third turning point… and that Erez believes could offer massive upside potential in the weeks and months ahead.

Case in point, the last time Erez released a watchlist like this was with the inaugural issue of Biotech Frontiers, and since then, our members have seen returns of:

• 87% on Kodiak Science…
• 49% on Nuvation Bio…
• 131% then another 237% on UniQure…
• 50% and 67% on a biotech developing therapeutics for metabolic dysfunction…
• 114% with TG Therapeutics…
• and more.

And remember, Erez delivered these results during the worst biotech bear market of all time, so just imagine what the results could be as the industry emerges from the ashes.

The combination of extraordinarily low valuations coinciding with biotechs third turning point has opened the doors to what could be a once-in-a-generation buying opportunity.

As Joel Drewry, a principal investor at Versant Ventures, says, biotech stocks have become so cheap that they are now “trading for nothing” and that the sector is “all upside from here.”

Industry veteran Dr. Ted Love says an “explosion is just around the corner for biotech” and that “now is when you really want to invest.”

Agustin Mohedas, a PhD in from Harvard, believes “the biotech sector is the biggest opportunity to generate alpha of any sector,” saying it is “filled with mispriced securities.”

And we don’t want you to be left behind…

Because at Porter & Co., we believe this is an incredible time to get involved in biotech – extremely low risk and potentially substantial upside – but only for those who act now.

This is your chance to do something truly rare: get into the next biotech bull market before it begins… while prices are still broken… while fear still dominates… while everyone else is still looking the other way.

And for those who do… we believe the upside potential could transform your financial future. It won’t be a straight line. It won’t be without risk. It won’t happen overnight.

But one thing is certain: This paradox will end.

And when it does, we believe Biotech Frontiers – especially Erez’s 10 new watchlist stocks – could deliver transformative long-term returns.

All of this is why we’re pulling out all the stops to make your decision to join Biotech Frontiers a no-brainer, with an exclusive offer we’ve never made before…

Until now, Biotech Frontiers has primarily been reserved for Partners in Porter & Co.

The cost to become a Partner is currently $12,500, and the annual value of Biotech Frontier is conservatively pegged at $5,000… but today you won’t need to pay anything close to that for access.

To help you capitalize on this investment paradox and what Erez calls “a generational buying opportunity,” we’re inviting you to join for just $2,000.

That’s a huge savings of $3,000 – a 60% discount.

As a member, you’ll get everything you need to take advantage of this rare window of opportunity, including:

All you’ve got to do is complete the secure order form below or call our offices at 844-933-9988 if you have any questions or would prefer to order over the phone.

So, if you want to capitalize on what may be the greatest financial paradox of all time and target potentially colossal returns during biotech’s third turning point… there is no better guide than Erez Kalir.

And there is no better time to get involved than right now.

We hope to see you inside.

Jared Kelly,

CEO, Porter & Co.